• Pre Clinical And Clinical Research

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine

- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment - Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills - New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics

CGT Catapult Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry

The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines to simplify and accelerate CRISPR gene editing workflows

QC-validated cell lines optimized to work alongside Horizon’s Edit-R predesigned sgRNA products and DharmaFECT transfection reagents

CTI Named #1 CRO in the World for Quality at 2020 Clinical and Research Excellence Awards

CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization (CRO) was named Champion in multiple categories of the 2020 CRO Leadership Awards, and was the only CRO named as Champion in the Quality category.

Life Sciences Recovery Roadmap

The COVID-19 crisis has powerfully demonstrated the strategic importance of the life science sector to the UK’s health, security, and to the economy.

UK precision medicine company PrecisionLife identifies 68 genes associated with high risk of severe COVID-19, suggesting opportunities for genomic biomarkers and new treatment options

25 June 2020, Oxfordshire, UK - Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.

Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting

Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR). The data concerns the company’s proprietary immunomodulatory agent, MDX-124, which has been shown to reduce cancer cell growth by up to 76% in a broad range of cancer cell lines.

Leaf Expression Systems Aids Research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) with the Development of Recombinant SARS-CoV-2 N-Protein

NORWICH, UK - 17 June 2020: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation based in Norwich, UK, has announced today that it has developed a recombinant SARS-CoV-2 N-protein (antigen) to aid research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) pandemic.

CiRA Foundation and the Cell and Gene Therapy Catapult set to launch new stem cell collaborative research

The companies will combine their expertise to explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicine products.